Search Results - "Hentsch, Bernd" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study

by Bitzer, Michael, Horger, Marius, Giannini, Edoardo G, Ganten, Tom M, Wörns, Marcus A, Siveke, Jens T, Dollinger, Matthias M, Gerken, Guido, Scheulen, Max E, Wege, Henning, Zagonel, Vittorina, Cillo, Umberto, Trevisani, Franco, Santoro, Armando, Montesarchio, Vincenzo, Malek, Nisar P, Holzapfel, Julia, Herz, Thomas, Ammendola, Astrid S, Pegoraro, Stefano, Hauns, Bernhard, Mais, Anna, Lauer, Ulrich M, Henning, Stefan W, Hentsch, Bernd
Published in Journal of hepatology (01.08.2016)

Get full text

Journal Article

Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure

Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure

by Zolk, Oliver, Frohme, Marcus, Maurer, Alexander, Kluxen, Franz-Werner, Hentsch, Bernd, Zubakov, Dimitri, Hoheisel, Jörg D, Zucker, Irving H, Pepe, Salvatore, Eschenhagen, Thomas
Published in Biochemical and biophysical research communications (24.05.2002)

Get full text

Journal Article

Abstract C040: INTH-454, a p300/CBP interactome modulator, targets multiple pathogenesis factors in solid tumors and induces strong anti-proliferative effects in vitro and in vivo as single agent

Abstract C040: INTH-454, a p300/CBP interactome modulator, targets multiple pathogenesis factors in solid tumors and induces strong anti-proliferative effects in vitro and in vivo as single agent

by Cattori, Valentino, Hentsch, Bernd, Kessler, Ulrich
Published in Molecular cancer therapeutics (01.12.2019)

Get full text

Journal Article

Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative xenograft models of castration-resistant prostate cancer (CRPC)

Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative xenograft models of castration-resistant prostate cancer (CRPC)

by Cattori, Valentino, Hentsch, Bernd, Kessler, Ulrich
Published in Journal of clinical oncology (20.05.2019)

Get full text

Journal Article

Abstract 2694: A first-in-class small-molecule modulator of the p300/CBP interactome exhibits broad efficacy in xenograft models of solid tumors and hematologic malignancies

Abstract 2694: A first-in-class small-molecule modulator of the p300/CBP interactome exhibits broad efficacy in xenograft models of solid tumors and hematologic malignancies

by Hentsch, Bernd, Cattori, Valentino, Labelle, Marc, Kessler, Ulrich
Published in Cancer research (Chicago, Ill.) (01.07.2019)

Get full text

Journal Article

Oral small molecule modulators of p300/CBP to reprogram cancer cells and reactivate the p53 pathway in HPV-associated carcinomas

Oral small molecule modulators of p300/CBP to reprogram cancer cells and reactivate the p53 pathway in HPV-associated carcinomas

by Kessler, Ulrich, Cattori, Valentino, Labelle, Marc, Hentsch, Bernd
Published in Journal of clinical oncology (20.05.2018)

Get full text

Journal Article

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

by BRUNETTO, André T, JOO ERN ANG, HAUNS, Bernhard, STROBEL, Vera, HENTSCH, Bernd, DE BONO, Johann S, LAI, Rohit, OLMOS, David, MOLIFE, L. Rhoda, KRISTELEIT, Rebecca, PARKER, Ann, CASAMAYOR, Isabel, OLALEYE, Muyibat, MAIS, Anna
Published in Clinical cancer research (01.10.2013)

Get full text

Journal Article

Population PK/PD analysis of the pan-HDAC inhibitor resminostat

Population PK/PD analysis of the pan-HDAC inhibitor resminostat

by Baumgartner, Roland, Henning, Stefan W., Hauns, Bernhard, Ammendola, Astrid, Krauss, Babett, Holzapfel, Julia, Bitzer, Michael, Hentsch, Bernd
Published in Journal of clinical oncology (20.05.2014)

Get full text

Journal Article

First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein

First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein

by Mross, Klaus B., Scharr, Dirk, Richly, Heike, Frost, Annette, Bauer, Sebastian, Krauss, Babett, Krauss, Rolf, Mais, Anna, Hauns, Bernhard, Hentsch, Bernd, Baumgartner, Roland, Scheulen, Max E.
Published in Journal of clinical oncology (20.05.2014)

Get full text

Journal Article

Centralized analysis of phase II ECG dataset of resminostat, an orally available histone-deacetylase inhibitor (HDACi)

Centralized analysis of phase II ECG dataset of resminostat, an orally available histone-deacetylase inhibitor (HDACi)

by Hauns, Bernhard, Schulze-Bergkamen, Henning, Jaeger, Dirk, Kopp, Hans-Georg, Bitzer, Michael, Krauss, Babett, Henning, Stefan W., Hentsch, Bernd, Haverkamp, Wilhelm
Published in Journal of clinical oncology (20.05.2014)

Get full text

Journal Article

Tu1875 Vidofludimus Induces p53-Mediated Apoptosis in Activated T Cells and Inhibits IL-17A and IL-17F Expression Decoupled From Lymphocyte Proliferation

Tu1875 Vidofludimus Induces p53-Mediated Apoptosis in Activated T Cells and Inhibits IL-17A and IL-17F Expression Decoupled From Lymphocyte Proliferation

by Hamm, Svetlana, Henning, Stefan W, Hentsch, Bernd, Vitt, Daniel, Groeppel, Manfred, Ammendola, Aldo
Published in Gastroenterology (New York, N.Y. 1943) (01.05.2012)

Get full text

Journal Article

Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: The SHORE trial

Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: The SHORE trial

by Schulze-Bergkamen, Henning, Jaeger, Dirk, Kopp, Hans-Georg, Mayer, Frank, Bitzer, Michael, Mais, Anna, Resemann, Karin, Hauns, Bernhard, Asche, Julia, Henning, Stefan W., Hentsch, Bernd
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article

First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study)

First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study)

by von Tresckow, Bastian, Gundermann, Stefan, Eichenauer, Dennis A., Aulitzky, Walter Erich, Göbeler, Mariele, Sayehli, Cyrus, Bacchus, Liza, Hauns, Bernhard, Mais, Anna, Hentsch, Bernd, Kohlhof, Hella, Krauss, Rolf, Krauss, Babett, Baumgartner, Roland, Vitt, Daniel, Engert, Andreas
Published in Journal of clinical oncology (20.05.2014)

Get full text

Journal Article

P-0082 Dose Escalation of the HDAC Inhibitor Resminostat in Combination Treatment with Sorafenib in Patients with Hepatocellular Carcinoma

P-0082 Dose Escalation of the HDAC Inhibitor Resminostat in Combination Treatment with Sorafenib in Patients with Hepatocellular Carcinoma

by Ganten, Tom, Wörns, Marcus-Alexander, Siveke, Jens, Dollinger, Matthias, Scheulen, Max, Wege, Henning, Mais, Anna, Hauns, Bernhard, Henning, Stefan, Hentsch, Bernd, Horger, Marius, Lauer, Ulrich, Bitzer, Michael
Published in Annals of oncology (01.06.2012)

Get full text

Journal Article

$Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma$

Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma

by Walewski, Jan, Paszkiewicz-Kozik, Ewa, Warszewska, Agnieszka, Borsaru, Gabriela, Moicean, Andreea, Hellmann, Andrzej, Mayer, Jiri, Hauns, Bernhard, Mais, Anna, Henning, Stefan W., Hentsch, Bernd
Published in Blood (18.11.2011)

Get full text

Journal Article

Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial

Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial

by Bitzer, Michael, Ganten, Tom M., Woerns, Marcus A., Siveke, Jens T., Dollinger, Matthias M., Scheulen, Max E., Wege, Henning, Giannini, Edoardo G., Cillo, Umberto, Trevisani, Franco, Santoro, Armando, Montesarchio, Vincenzo, Mais, Anna, Hauns, Bernhard, Asche, Julia, Herz, Thomas, Pegoraro, Stefano, Ammendola, Aldo, Henning, Stefan W., Hentsch, Bernd
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article

Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study

Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study

by Bitzer, Michael, Horger, Marius, Ganten, Tom M, Siveke, Jens T, Woerns, Marcus A, Dollinger, Matthias M., Gerken, Guido, Scheulen, Max E., Wege, Henning, Giannini, Edoardo G, Montesarchio, Vincenzo, Mais, Anna, Jankowsky, Rüdiger, Hauns, Bernhard, Hentsch, Bernd, Lauer, Ulrich
Published in Journal of clinical oncology (01.02.2012)

Get full text

Journal Article

$Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor$

Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor

by Walewski, Jan, Paszkiewicz-Kozik, Ewa, Borsaru, Gabriela, Moicean, Andreea, Warszewska, Agnieszka, Strobel, Klaus, Biggi, Alberto, Hauns, Bernhard, Mais, Anna, Henning, Stefan W., Hentsch, Bernd
Published in Blood (19.11.2010)

Get full text

Journal Article

$Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study$

Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study

by Bitzer, Michael, Horger, Marius, Ganten, Tom M, Lauer, Ulrich M, Woerns, Marcus A, Siveke, Jens T, Dollinger, Matthias M., Gerken, Guido, Wege, Henning, Giannini, Edoardo G, Zagonel, Vittorina, Cillo, Umberto, Trevisani, Franco, Santoro, Armando, Montesarchio, Vincenzo, Hauns, Bernhard, Asche, Julia, Jankowsky, Rüdiger, Mais, Anna, Hentsch, Bernd
Published in Journal of clinical oncology (20.05.2012)

Get full text

Journal Article

Efficacy, Safety and Tolerability of Vidofludimus in Patients With Inflammatory Bowel Disease: The ENTRANCE Study

Efficacy, Safety and Tolerability of Vidofludimus in Patients With Inflammatory Bowel Disease: The ENTRANCE Study

by Herrlinger, Klaus R, Diculescu, Mircea M, Fellermann, Klaus, Hartmann, Heinz, Howaldt, Stefanie M, Nikolov, Rosen, Petrov, Asen, Reindl, Wolfgang, Otte, Jan-Michel, Stoinov, S, Strauch, Ulrike, Sturm, Andreas, Voiosu, Radu M, Ammendola, Aldo, Dietrich, Bruno, Hentsch, Bernd, Stange, Eduard
Published in Gastroenterology (New York, N.Y. 1943) (2011)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
Next
[10]